210 related articles for article (PubMed ID: 8301059)
1. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
[TBL] [Abstract][Full Text] [Related]
2. [Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases].
Carreño García V; Hernández-Guío C; Bartolomé Nebreda J; Quiroga Estévez JA
Rev Esp Enferm Dig; 1993 Mar; 83(3):169-75. PubMed ID: 7683894
[TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of circulating endogenous granulocyte-macrophage colony-stimulating factor in HIV-1-seropositive injecting drug users.
Herold M; Meise U; Günther V; Rössler H; Zangerle R
Presse Med; 1994 Dec; 23(40):1854-8. PubMed ID: 7899316
[TBL] [Abstract][Full Text] [Related]
4. Serum and urinary neopterin levels in patients with chronic active hepatitis B treated with interferon.
Daito K; Suou T; Kawasaki H
Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):303-16. PubMed ID: 8008980
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B.
Martin J; Bosch O; Moraleda G; Bartolome J; Quiroga JA; Carreño V
Hepatology; 1993 Oct; 18(4):775-80. PubMed ID: 8406350
[TBL] [Abstract][Full Text] [Related]
6. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
Hofmann B; Bass H; Nishanian P; Faisal M; Figlin RA; Sarna GP; Fahey JL
Clin Exp Immunol; 1992 Jun; 88(3):548-54. PubMed ID: 1606739
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
8. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.
Boccoli G; Masciulli R; Ruggeri EM; Carlini P; Giannella G; Montesoro E; Mastroberardino G; Isacchi G; Testa U; Calabresi F
Cancer Res; 1990 Sep; 50(18):5795-800. PubMed ID: 2118421
[TBL] [Abstract][Full Text] [Related]
11. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
[TBL] [Abstract][Full Text] [Related]
12. Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B.
Martín J; Quiroga JA; Bosch O; Carreño V
Hepatology; 1994 Nov; 20(5):1156-61. PubMed ID: 7927247
[TBL] [Abstract][Full Text] [Related]
13. [Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C].
Daito K; Suou T; Kawasaki H
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):981-5. PubMed ID: 7563914
[No Abstract] [Full Text] [Related]
14. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases.
Monsalve-De Castillo F; Romero TA; Estévez J; Costa LL; Atencio R; Porto L; Callejas D
Clin Diagn Lab Immunol; 2002 Nov; 9(6):1372-5. PubMed ID: 12414777
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.
Carreño V; Zeuzem S; Hopf U; Marcellin P; Cooksley WG; Fevery J; Diago M; Reddy R; Peters M; Rittweger K; Rakhit A; Pardo M
J Hepatol; 2000 Feb; 32(2):317-24. PubMed ID: 10707873
[TBL] [Abstract][Full Text] [Related]
16. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
17. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
[TBL] [Abstract][Full Text] [Related]
18. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
19. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
[TBL] [Abstract][Full Text] [Related]
20. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.
Fuchs D; Norkrans G; Wejstal R; Reibnegger G; Weiss G; Weiland O; Schvarcz R; Fryden A; Wachter H
Eur J Med; 1992; 1(4):196-200. PubMed ID: 1341444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
